Candel Therapeutics, a clinical-stage biopharmaceutical company, has made significant strides in the fight against cancer with the recent announcement of their Phase 3 trial results for CAN-2409, a novel viral immunotherapy designed to treat localized prostate cancer. This milestone not only marks a pivotal moment for the company but also potentially reshapes the therapeutic landscape of prostate cancer management. Key Findings from the Phase 3 Trial The trial aimed to evaluate the efficacy of CAN-2409 compared to placebo, focusing primarily on its ability to improve disease-free survival (DFS) among patients with localized prostate cancer. Candel Therapeutics reported that CAN-2409 met its primary endpoint,...
In a groundbreaking announcement, Candel Therapeutics, Inc., a leading clinical-stage biopharmaceutical company dedicated to advancing multimodal biological immunotherapies to combat cancer, specified two significant abstracts had been accepted for presentation at the imminent 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The esteemed event will take place from May 31 to June 4, 2024, in Chicago, IL. These showcases will reveal pivotal early-stage data related to two proprietary investigational therapies specifically designed for patients with recurrent high-grade glioma and advanced non-small cell lung cancer (NSCLC).The first presentation will unfold insights regarding an ongoing phase ...
Candel Therapeutics, a clinical-stage biopharmaceutical firm with a strong emphasis on the development of multimodal biological immunotherapies for cancer patients, recently unveiled preclinical data at the AACR Annual Meeting in San Diego. The information revolved around an innovative first-in-class multimodal immunotherapy candidate aimed at inducing tertiary lymphoid structures (TLS) in solid tumors, courtesy of Candels enLIGHTEN Discovery Platform.The enLIGHTEN Discovery Platform facilitates the development of a unique therapeutic strategy for tackling solid tumors, making this advancement a notable feat. Additionally, the potential of the multimodal immunotherapy approach in stimulating a robust anti-tu...
Candel Therapeutics, a renowned biotechnology company, has been making significant strides in recent times, propelling itself towards a highly promising future in 2024. With a focus on key value drivers and effective catalysts, the company has achieved noteworthy benchmarks that demand attention. This article aims to outline the prominent achievements of Candel Therapeutics and explore the factors that have contributed to its path of success.The Foundation of Candel Therapeutics:Candel Therapeutics, established in year, operates as a cutting-edge biotechnology firm that specializes in the development of innovative therapeutics for critical diseases. With a mission to improve human health through advanced med...
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409 NEEDHAM, Mass., Nov. 28, 2023 - Candel Therapeutics, a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, has recently made a strategic decision to restructure its operations. The aim of this restructuring is to concentrate on the continuation and expansion of the development of CAN-3110 and the enLIGHTEN Discovery Platform. As part of this strategic shift, Candel will be reducing its workforce and expenses associated with enabling the com...
Sources:
Candel Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Candel Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Candel Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
